The S1P receptor modulator FTY720 prevents the development of experimental colitis in mice

Oncology Reports

Volumn 16, Issue 4, 2006, Pages 699-703

  Deguchi, Yasuyuki ^a   Andoh, Akira ^a   Yagi, Yuki ^a   Bamba, Shigeki ^a   Inatomi, Osamu ^a   Tsujikawa, Tomoyuki ^a   Fujiyama, Yoshihide ^a  

^a SHIGA UNIVERSITY OF MEDICAL SCIENCE   (Japan)

Author keywords

DSS colitis; Immunosuppressant

Indexed keywords

DRUG DERIVATIVE; FINGOLIMOD; IMMUNOSUPPRESSIVE AGENT; L SELECTIN; PROPANEDIOL DERIVATIVE; SPHINGOSINE; SPHINGOSINE 1 PHOSPHATE RECEPTOR;

ANIMAL; ARTICLE; BAGG ALBINO MOUSE; BIOSYNTHESIS; CD4+ T LYMPHOCYTE; CELL TRANSPLANTATION; COLITIS; DISEASE MODEL; ENTERITIS; MALE; METABOLISM; MOUSE; MOUSE MUTANT; PHYSIOLOGY; SPLEEN;

ANIMALS; CD4-POSITIVE T-LYMPHOCYTES; CELL TRANSPLANTATION; COLITIS; DISEASE MODELS, ANIMAL; IMMUNOSUPPRESSIVE AGENTS; INFLAMMATORY BOWEL DISEASES; L-SELECTIN; MALE; MICE; MICE, INBRED BALB C; MICE, SCID; PROPYLENE GLYCOLS; RECEPTORS, LYSOSPHINGOLIPID; SPHINGOSINE; SPLEEN;

EID: 35748943897     PISSN: 1021335X     EISSN: 17912431     Source Type: Journal    
DOI: 10.3892/or.16.4.699     Document Type: Article

References (21)

1. Podolsky DK: Lessons from genetic models of inflammatory bowel disease. Acta Gastroenterol Belg 60: 163-165, 1997.
2. Podolsky DK: The future of IBD treatment. J Gastroenterol 38 (Suppl. 15): S63-S66, 2003.
3. Podolsky DK: IBD: the dialectic of clinical advances and challenges. Dig Liver Dis 37: 1-2, 2005.
4. Hibi T and Ogata H: Novel pathophysiological concepts of inflammatory bowel disease. J Gastroenterol 41: 10-16, 2006.
5. Yopp AC, Fu S, Honig SM, Randolph GJ, Ding Y, Krieger NR and Bromberg JS: FTY720-enhanced T cell homing is dependent on CCR2, CCR5, CCR7 and CXCR4: evidence for distinct chemokine compartments. J Immunol 173: 855-865, 2004. (Pubitemid 38924259)
6. Bandhuvula P, Tam YY, Oskouian B and Saba JD: The immune modulator FTY720 inhibits sphingosine-1-phosphate lyase activity. J Biol Chem 280: 33697-33700, 2005. (Pubitemid 41443086)
7. Kharel Y, Lee S, Snyder AH, Sheasley-O'neill S L, Morris MA, Setiady Y, Zhu R, Zigler MA, Burcin TL, Ley K, Tung KS, Engelhard VH, Macdonald TL, Pearson-White S and Lynch KR: Sphingosine kinase 2 is required for modulation of lymphocyte traffic by FTY720. J Biol Chem 280: 36865-36872, 2005.
8. Muller H, Hofer S, Kaneider N, Neuwirt H, Mosheimer B, Mayer G, Konwalinka G, Heufler C and Tiefenthaler M: The immunomodulator FTY720 interferes with effector functions of human monocyte-derived dendritic cells. Eur J Immunol 35: 533-545, 2005. (Pubitemid 40331330)
9. Pabst O, Herbrand H, Willenzon S, Worbs T, Schippers A, Muller W, Bernhardt G and Forster R: Enhanced FTY720-mediated lymphocyte homing requires G{alpha}i signaling and depends on beta2 and beta7 integrin. J Immunol 176: 1474-1480, 2006. (Pubitemid 43134290)
10. +T-regulatory cells and enhances their functional activity. J Immunol 175: 7973-7980, 2005.
11. Sawicka E, Zuany-Amorim C, Manlius C, Trifilieff A, Brinkmann V, Kemeny DM and Walker C: Inhibition of Th1-and Th2-mediated airway inflammation by the sphingosine 1-phosphate receptor agonist FTY720. J Immunol 171: 6206-6214, 2003. (Pubitemid 37467244)
12. Pabst O, Herbrand H, Willenzon S, Worbs T, Schippers A, Muller W, Bernhardt G and Forster R: Enhanced FTY720-mediated lymphocyte homing requires Galphai signaling and depends on beta2 and beta7 integrin. J Immunol 176: 1474-1480, 2006. (Pubitemid 43134290)
13. Mizushima T, Ito T, Kishi D, Kai Y, Tamagawa H, Nezu R, Kiyono H and Matsuda H: Therapeutic effects of a new lymphocyte homing reagent FTY720 in interleukin-10 gene-deficient mice with colitis. Inflamm Bowel Dis 10: 182-192, 2004. (Pubitemid 38618245)
14. Egger B, Bajaj-Elliott M, MacDonald TT, Inglin R, Eysselein VE and Buchler MW: Characterisation of acute murine dextran sodium sulphate colitis: cytokine profile and dose dependency. Digestion 62: 240-248, 2000.
15. Neurath MF, Weigmann B, Finotto S, Glickman J, Nieuwenhuis E, Iijima H, Mizoguchi A, Mizoguchi E, Mudter J, Galle PR, Bhan A, Autschbach F, Sullivan BM, Szabo SJ, Glimcher LH and Blumberg RS: The transcription factor T-bet regulates mucosal T cell activation in experimental colitis and Crohn's disease. J Exp Med 195: 1129-1143, 2002. (Pubitemid 34517139)
16. +T cells which prevent intestinal inflammation in the SCID transfer model of colitis. Gut 54: 1428-1436, 2005.
17. Cooper HS, Murthy SN, Shah RS and Sedergran DJ: Clinicopathologic study of dextran sulfate sodium experimental murine colitis. Lab Invest 69: 238-249, 1993.
18. Brinkmann V and Lynch KR: FTY720: targeting G-protein-coupled receptors for sphingosine 1-phosphate in transplantation and autoimmunity. Curr Opin Immunol 14: 569-575, 2002.
19. Brinkmann V: FTY720: mechanism of action and potential benefit in organ transplantation. Yonsei Med J 45: 991-997, 2004.
20. Tedesco-Silva H, Mourad G, Kahan BD, Boira JG, Weimar W, Mulgaonkar S, Nashan B, Madsen S, Charpentier B, Pellet P and Vanrenterghem Y: FTY720, a novel immunomodulator: efficacy and safety results from the first phase 2A study in de novo renal transplantation. Transplantation 79: 1553-1560, 2005. (Pubitemid 40847587)
21. Sivakumar PV, Westrich GM, Kanaly S, Garka K, Born TL, Derry JM and Viney JL: Interleukin 18 is a primary mediator of the inflammation associated with dextran sulphate sodium induced colitis: blocking interleukin 18 attenuates intestinal damage. Gut 50: 812-820, 2002. (Pubitemid 34539043)